Palatin Tech SEC Filings

Palatin Technologies, Inc. plans to move its common stock listing from the NYSE American to the Nasdaq Capital Market. Trading on the NYSE American is expected to end on May 28, 2026, with Nasdaq trading beginning May 29, 2026, under the same symbol “PTN.”

The company develops melanocortin receptor–targeted therapies, including selective MC4R-based obesity programs for rare disorders such as hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome. A once-weekly injectable MC4R agonist is targeted for an IND submission in the fourth quarter of 2026, and an oral MC4R agonist candidate is targeted for IND submission in the first half of 2027.

Palatin Technologies Inc reports that Logos Global and related reporting persons each beneficially own 182,162 shares of Common Stock, representing 9.9% of the class.

The filing states the percentage calculation references 1,779,275 shares outstanding as of May 12, 2026 and discloses warrants to acquire 224,000 shares plus an alternate beneficially owned count of 137,992 shares used in the percentage calculation. The reporting persons say the securities are held on behalf of Logos Opportunities Fund IV and that they disclaim group membership and broader beneficial ownership beyond their pecuniary interest.

Palatin Technologies, Inc. filed Amendment No. 1 to a Schedule 13G/A reporting beneficial ownership of 8,600 shares of Common Stock, representing 0.5% of the class as of the close of business on 03/31/2026. The statement lists Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen as the reporting persons and discloses that the shares are held by an investment fund managed by Point72 Asset Management; the filing notes shared voting and dispositive power of 8,600 shares.

Palatin Technologies disclosed that Sirenia Capital Management LP and Alex Silverstein report beneficial ownership of 2,307,000 shares of Common Stock, representing 9.9% of the class based on 1,772,199 shares outstanding as of February 13, 2026. The reported amount includes 2,192,000 shares issuable upon exercise of warrants, but those warrants are subject to a 9.99% Blocker that limits exercise. The filing is a joint Schedule 13G by Sirenia and Mr. Silverstein and states the percentages give effect to the Blocker.

Palatin Technologies reported its quarterly results for the period ended March 31, 2026, showing it is shifting from pure R&D funding toward collaboration-driven revenue. Collaboration and license revenue reached $3.9 million for the quarter and $12.9 million for the nine months, compared with no revenue in the prior-year periods, driven mainly by a $3.75 million non-cash license to Altanispac Labs and earlier payments under its Boehringer Ingelheim retinal disease agreement. Operating expenses remained high, with research and development at $3.5 million and general and administrative at $2.0 million for the quarter. Net loss narrowed to $1.43 million for the quarter and $4.02 million year-to-date. Cash and cash equivalents improved to $10.2 million, supported by multiple 2025 equity and warrant financings totaling tens of millions of dollars, and stockholders’ equity turned positive at $10.6 million. Management still highlights long-term funding needs but believes current cash will fund operations for at least twelve months.

AuGC BioFund LP and related filers report beneficial ownership of 5.3% of Palatin Technologies common stock. The filers state they each have beneficial ownership of 94,212 shares of Common Stock of Palatin Technologies Inc.

The ownership percentage is based on 1,772,199 shares outstanding as of February 13, 2026. The statement discloses shared voting and shared dispositive power over 94,212 shares and includes an express disclaimer under Rule 13d-4 regarding beneficial ownership.

Palatin Technologies reported a larger quarterly loss but a stronger balance sheet in its quarter and six months ended December 31, 2025. Collaboration and license revenue reached $8.96 million for the six-month period, all from a new agreement with Boehringer Ingelheim, compared with no revenue a year earlier.

The company posted a net loss of $7.26 million for the quarter and $2.59 million for six months, narrower than the prior-year six‑month loss. Cash and cash equivalents rose to $14.48 million, up from $2.56 million at June 30, 2025, helped by multiple equity and warrant financings.

Palatin continues to invest heavily in melanocortin receptor programs for obesity and inflammatory diseases while transitioning prior assets to partners. Management expects existing cash to fund operations for at least 12 months after the statements’ issuance but acknowledges the need for substantial additional funding to advance its pipeline.

Driehaus Capital Management LLC, a Delaware investment adviser, reported beneficial ownership of 166,713 shares of Palatin Technologies, Inc. common stock, representing 9.79% of the class as of 12/31/2025. Driehaus has shared power to vote and dispose of all these shares, with no sole voting or dispositive power.

The shares are held in fully discretionary accounts for investment advisory clients, including Driehaus Life Sciences Master Fund, L.P., which retain the right to receive dividends and sale proceeds. Driehaus certifies that the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Palatin.

Palatin Technologies, Inc. reported insider equity tax-withholding transactions by an executive vice president and CFO/COO. On December 30, 2025, the officer had small amounts of common stock withheld by the company to cover employee withholding taxes tied to previously vested equity grants.

The filing shows three transactions coded "F" at a per-share value of $21.38, withholding 26, 91, and 95 shares from grants of 95, 330, and 345 shares that vested on December 8, 2025. After these tax-related withholdings, the officer reported beneficial ownership of 63,462, 63,371, and 63,276 shares of Palatin common stock in successive entries, all held directly.